echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > "Pick/Merge" antigen design: a new strategy for universal vaccine design without fear of variants

    "Pick/Merge" antigen design: a new strategy for universal vaccine design without fear of variants

    • Last Update: 2021-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Approximately 1.


    It’s all about the antigen

    The working principle of a vaccine is to train the immune system to recognize and respond to infections by specific pathogens (such as viruses, parasites, or bacteria)


    In order to solve this problem, Baseimmune's vaccine design algorithm integrates genomic, epidemiological, immunological, clinical and evolutionary data to create a new synthetic antigen, which contains all pathogens "most likely to elicit strong protective immunity.


    These "select and mix" antigens will effectively provide the immune system with all the tools the immune system may need to know about how to recognize and respond to specific pathogens-now or in the future, with or without mutation


    For example, the company recently collaborated with DNA vaccine pioneer Touchlight to develop a universal coronavirus vaccine designed to respond to the emergence of new mutations and prevent future pandemics


    As early as January 2020, the Baseimmune team input a small amount of data about SARS-CoV-2 into their algorithm, correctly predicting that major mutations such as Alpha and Delta will not appear in the coming year


    Co-founder Phillip Kemlo is a software engineer who built predictive algorithms.


    Universal vaccine for malaria, COVID and other diseases

    Baseimmune was established in 2019 to design and develop universal future vaccines for human and animal infections, including malaria, COVID and African swine fever


    Co-founder Josh Blight is currently working at Imperial College London.


    Co-founder Ariane Gomes said: “I grew up in Brazil and witnessed the impact of infectious diseases, just like my aunt lived with polio (a vaccine-preventable disease).


    Jake Baum, a scientific consultant and professor of cell biology and infectious diseases at Imperial College London, is working with the team to develop a new malaria vaccine




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.